In this randomized trial, dalbavancin didn't result in improved outcomes versus standard treatment for adults with complicated Staphylococcus aureus bacteremia. Rates of adverse events leading to ...

Please provide your email address to receive an email when new articles are posted on . Dalbavancin requires two doses 7 days apart, compared with standard 4- to 8-week therapy for S. aureus ...

Research comparing clinical outcomes between patients receiving nafcillin and cefazolin for treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia shows that overall treatment ...

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...

LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific ...